Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Yvette Drew Jae-Weon Kim Richard T Penson David M O'Malley Christine Parkinson Patricia Roxburgh Ruth Plummer Seock-Ah Im Martina Imbimbo Michelle Ferguson Ora Rosengarten Neeltje Steeghs Min Hwan Kim Einav Nili Gal-Yam Daliah Tsoref Jae-Hoon Kim Benoit You Maja J A de Jonge Roy I Lalisang Eelke H Gort Sara Bastian Kassondra Meyer Laura Feeney Nigel Baker Mei-Lin Ah-See Susan M Domchek Susana Banerjee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Olaparib plus durvalumab continued to show notable clinical activity in women with gBRCAm PSROC. Olaparib plus durvalumab with bevacizumab demonstrated encouraging clinical activity in women with non-gBRCAm PSROC. No new safety signals were identified.

Keyphrases

phase ii
clinical trial
open label
acute lymphoblastic leukemia
metastatic colorectal cancer
multiple myeloma
combination therapy
study protocol